Home > Products > Antibodies > Neutralizing Antibodies

InVivoMAb Anti-SARS-CoV-2 Spike Protein Antibody (Iv0205) (VK565040)

Datasheet Share product Copy info

InVivoMAb Anti-SARS-CoV-2 Spike Protein Antibody (Iv0205)

InVivoMAb Anti-SARS-CoV-2 Spike Protein Antibody (Iv0205)

Price(USD): $

Spec:

100ug
1mg

Number:

Contact us

Overview
Images
References
Datasheet

Overview

Catalog No.	VK565040
Description	InVivoMAb Anti-SARS-CoV-2 Spike Protein Antibody (Iv0205) [Iv0205] (VK565040) is a human monoclonal antibody detecting Spike in ELISA, Neutralization.
Species reactivity	SARS-CoV-2(2019-nCoV)
Applications	ELISA, Neutralization
Host species	Human
Isotype	IgG1, kappa
Clone ID	Iv0205
Clonality	Monoclonal
Target	Spike
Endotoxin level	Please contact with the lab for this information.
Purity	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P0DTC2
RRID	InVivoMAb Anti-SARS-CoV-2 Spike Protein Antibody (Iv0205) (abinScience Cat# VK565040, RRID:AB_3729077)
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Background	Spike glycoprotein (RBD) is a ~141 kDa protein. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2. When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane. When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis using host TFRC and GRM2 and leading to fusion of the virion membrane with the host endosomal membrane. Alternatively, may use NRP1/NRP2 and integrin as entry receptors. 1. Hoffmann, M. et al. (2020) Cell 181, 271-280.e8. PMID: 32142651 2. Walls, AC. et al. (2020) Cell 181, 281-292.e6. PMID: 32155444 3. Cao, W. et al. (2021) Biophysical journal 120, 1011-1019. PMID: 33607086 4. Takeda, M. (2022) Microbiology and immunology 66, 15-23. PMID: 34561887 5. Wrapp, D. et al. (2020) Science (New York, N.Y.) 367, 1260-1263. PMID: 32075877 6. Ou, X. et al. (2020) Nature communications 11, 1620. PMID: 32221306 7. Wang, J. et al. (2021) Cell discovery 7, 119. PMID: 34903715 8. Wang, X. et al. (2023) Journal of virology 97, e0161122. PMID: 36779763 9. Daly, JL. et al. (2020) Science (New York, N.Y.) 370, 861-865. PMID: 33082294 10. Cantuti-Castelvetri, L. et al. (2020) Science (New York, N.Y.) 370, 856-860. PMID: 33082293
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

SDS-PAGE

SDS-PAGE for InVivoMAb Anti-SARS-CoV-2 Spike Protein Antibody (Iv0205).

References

Datasheet

InVivoMAb Anti-SARS-CoV-2 Spike Protein Antibody (Iv0205).pdf

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

=

Concentration

×

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

×

V₁ (Stock Vol.)

=

Working Solution

C₂ (Working Conc.)

×

V₂ (Working Vol.)

Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: support@abinScience.com

Distributor list

InVivoMAb Anti-SARS-CoV-2 Spike Protein Antibody (Iv0205)